#PSMA_PET
Clarity Pharmaceuticals Receives First FDA Breakthrough Therapy Designation for Prostate Cancer Imaging#Australia#Sydney#Prostate_Cancer#Clarity_Pharmaceuticals#PSMA_PET
Clarity Pharmaceuticals Receives First FDA Breakthrough Therapy Designation for Prostate Cancer Imaging
Clarity Pharmaceuticals has gained FDA Breakthrough Therapy designation for 64Cu-SAR-bisPSMA in detecting prostate cancer recurrence, marking a significant milestone in cancer imaging.
third-news.com
November 12, 2026 at 2:21 PM